$RYTM filed an 8-K with results (Item 2.02) at 8:10 AM ET on Tue, Nov 3.
Vote
RYTM
Rhythm Pharmaceuticals, Inc.$87.46CS band Caution
−$7.00 (7.49%) At close $86.44 · Today
☾After Hours +$1.02 (1.18%) Nov 3, 7:59 PM ET
About RYTM
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Board
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›